BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 15216448)

  • 21. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart.
    Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
    Scand J Clin Lab Invest; 2008; 68(8):739-44. PubMed ID: 19016075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T
    Coll Antropol; 2003 Jun; 27(1):181-7. PubMed ID: 12974145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
    Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
    Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
    Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L; Mannucci E; Dicembrini I; Rotella CM
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
    Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
    Ogawa S; Takeuchi K; Ito S
    Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB; Al Majali K; Bailey CJ; Betteridge DJ
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK; Sibal L; Ashwell SG; Home PD
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.